Press coverage about Alimera Sciences (NASDAQ:ALIM) has been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alimera Sciences earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.7141354836874 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

Several brokerages have weighed in on ALIM. HC Wainwright set a $5.00 price objective on Alimera Sciences and gave the stock a “buy” rating in a report on Tuesday, July 11th. Zacks Investment Research raised Alimera Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, June 13th. Cowen and Company reissued a “buy” rating and set a $3.00 price objective on shares of Alimera Sciences in a report on Tuesday, July 11th. Finally, ValuEngine cut Alimera Sciences from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Alimera Sciences has an average rating of “Hold” and an average target price of $3.38.

Shares of Alimera Sciences (NASDAQ:ALIM) traded down 0.71% during mid-day trading on Wednesday, hitting $1.40. The stock had a trading volume of 73,617 shares. The stock’s 50-day moving average is $1.44 and its 200-day moving average is $1.43. The firm’s market capitalization is $96.67 million. Alimera Sciences has a 1-year low of $1.03 and a 1-year high of $1.72.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. The company had revenue of $10.40 million for the quarter, compared to the consensus estimate of $10.20 million. During the same quarter last year, the business earned ($0.17) earnings per share. Alimera Sciences’s revenue was up 8.3% compared to the same quarter last year. Equities analysts expect that Alimera Sciences will post ($0.21) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/13/alimera-sciences-alim-receives-daily-news-sentiment-rating-of-0-19.html.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Insider Buying and Selling by Quarter for Alimera Sciences (NASDAQ:ALIM)

Receive News & Stock Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related stocks with our FREE daily email newsletter.